Ê×´æ1ÔªËÍ22²Ê½ð

µ±Ç°Î»Ö㺠ÍøÕ¾Ê×Ò³ > ÐÂÎŶ¯Ì¬ > ÕýÎÄ

ÐÂÎŶ¯Ì¬
ÐÂÎŶ¯Ì¬
Ê×´æ1ÔªËÍ22²Ê½ð½üÆÚÖصã¿ÆÑÐËÙÀÀ
À´Ô´£º¡°ÈÊÐÄ¡±Í¨Ñ¶Éç¡¡µÚÒ»¸½ÊôÒ½Ôº¡¡»ù´¡Ò½Ê×´æ1ÔªËÍ22²Ê½ð¡¡Ò©Ê×´æ1ÔªËÍ22²Ê½ð    ÈÕÆÚ£º2024-06-04     ä¯ÀÀ´ÎÊý£º
¡¡¡¡½üÆÚ£¬Ê×´æ1ÔªËÍ22²Ê½ðÊ×´æ1ÔªËÍ22²Ê½ðÈ¡µÃ¶àÏî¿ÆÑÐÐÂÍ»ÆÆ£¬Ë¶¹ûÀÛÀÛ£¬³É¾ÍÆÄ·á¡£ÌØÑ¡²¿·ÖÖصã¿ÆÑгɹûËÙÀÀ»Ø¹Ë¡£
Ê×´æ1ÔªËÍ22²Ê½ðÒ½¹¤Ð­×÷ÍŶÓÔÚÈ«ÉíÂé×íÒ©Îï¼õ¶¾ÔöЧ·½ÃæÈ¡µÃÖØÒª½øÕ¹
¡¡
¡¡¡¡½üÈÕ£¬Ê×´æ1ÔªËÍ22²Ê½ðÉúÃü¿ÆѧÓë¼¼ÊõÊ×´æ1ÔªËÍ22²Ê½ð²©Ê¿ÉúÕÅ˸ΪµÚÒ»×÷Õߣ¬ÉúÃü¿ÆѧÓë¼¼ÊõÊ×´æ1ÔªËÍ22²Ê½ðÎâµÀ³Î½ÌÊں͵ÚÒ»¸½ÊôÒ½ÔºÂé×íÊÖÊõ²¿¸±Ö÷ÈθßΡ¸±Ö÷ÈÎҽʦΪ¹²Í¬Í¨Ñ¶×÷Õߣ¬ÔÚÖøÃûÆÚ¿¯¡¶¾Û¼¯Ìå¡·£¨Aggregate, IF=18.8£©ÉÏÔÚÏß·¢±íÒÔÌâΪ¡¶³¬ÉùÁªºÏѪÄÔÆÁÕÏ°ÐÏò·Ö×ÓµÝËÍËĺÏÒ»·Ö×Ó¾Û¼¯ÌåÈëÄÔͨ¹ýÒì±û·Ó-ÒÀÍÐßäõ¥Ð­Í¬ÒÖÖÆGABAÊÜÌåÀ´ÔöÇ¿Âé×íЧ¹û²¢½µµÍ¶¾ÐÔ¡·µÄÑо¿ÂÛÎÄ¡£¸Ã¹¤×÷µÃµ½Á˹ú¼Ò×ÔÈ»¿Æѧ»ù½ð¡¢ÉÂÎ÷Ê¡¡°¸ß²ã´ÎÈ˲ÅרÏîÖ§³Ö¼Æ»®¡±ÇàÄê°Î¼âÈ˲ÅÏîÄ¿µÄ×ÊÖú¡£Ê×´æ1ÔªËÍ22²Ê½ð·ÖÎö²âÊÔÖÐÐĺÍÉúÎïҽѧʵÑéÖÐÐÄΪ±¾¹¤×÷ÌṩÁË´óÁ¿Ñо¿Ö§³Ö¡£
µÚÒ»¸½ÊôÒ½ÔººÎÍúæç¿ÆÑÐÍŶÓÔÚÖ×ÁöÃâÒßÖÎÁÆ΢µ°°×Ò©ÎïÉè¼Æ·½Ãæ±³¿¿±³·¢±íÑо¿³É¹û
¡¡¡¡Ê×´æ1ÔªËÍ22²Ê½ðµÚÒ»¸½ÊôÒ½ÔººÎÍúæçÑо¿Ô±ÎªÎÄÕÂͨѶ×÷Õߣ¬Ö×ÁöÄڿƽ¯°®Ãñ²©Ê¿Îª±¾ÎĵÚÒ»×÷Õߣ¬ÔÚÖøÃûÆÚ¿¯¡¶ACS Nano¡·£¨IF=17.1£©ÉÏ·¢±íÌâΪ¡°Advancing the boundaries of immunotherapy in lung adenocarcinoma with idiopathic pulmonary fibrosis by a biomimetic proteinoid enabling selective endocytosis¡±µÄ¿ÆÑÐÂÛÎÄ¡£
µÚÒ»¸½ÊôÒ½ÔºÖ×Áö·ÅÁÆ¿ÆÕÔ¶«Àû½ÌÊÚÍŶÓÔÚ¡¶ÁøÒ¶µ¶¡·Õý¿¯·¢±íÖØÒªÑо¿ÆÀÊöÎÄÕÂ
¡¡¡¡µÚÒ»×÷ÕßÕÔ¶«Àû½ÌÊÚ¡¢Í¨Ñ¶×÷Õß·ӽ¿­ÎïÀíʦ£¨¹²Í¬×÷ÕßÀîÒã¸ß¼¶¹¤³Ìʦ¡¢ÇúÒÔƽÖ÷ÖÎҽʦºÍºÎ³¿è¡Ö÷ÖÎҽʦ£©ÔÚ¡¶ÁøÒ¶µ¶¡·£¨IF=168.9£©ÉϵÄcorrespondenceרÀ¸ÉÏ·¢±íÒÔ¡°Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial£¨SIBÈéÏÙ·ÅÉäÖÎÁÆÃæÁÙµÄÌôÕ½£ºIMPORT HIGHÊÔÑ飩¡±ÎªÌâµÄÎÄÕ¡£
»ù´¡Ò½Ê×´æ1ÔªËÍ22²Ê½ðÍŶÓÑо¿·¢±íÖáÍ»ÄÒÅÝɸѡлúÖÆ
¡¡¡¡Ê×´æ1ÔªËÍ22²Ê½ð»ù´¡Ò½Ê×´æ1ÔªËÍ22²Ê½ðÑîÌÊÚ£¬ÍŶӳÉÔ±²©Ê¿ºóº«ÔÀ¡¢ÁõÕÜ£¬²©Ê¿ÉúÀîÃô£¬Ñо¿ÉúÕÔ±ùÇå¡¢ÁõÑà¡¢Íõ»Û³¬£¬ÔÚ¡¶ÃÀ¹ú¿ÆÊ×´æ1ÔªËÍ22²Ê½ðÔº¿¯¡·(PNAS)ÉÏ·¢±íÌâΪ¡¶MARK2Á×ËữKIF13AµÄ14-3-3½áºÏλµãµ÷¿ØתÌúµ°°×ÊÜÌåÄÒÅÝÔÚÊ÷Í»Éϵļ«»¯×ªÔË¡·£¨MARK2 phosphorylates KIF13A at a 14-3-3 binding site to polarize vesicular transport of transferrin receptor within dendrites£©µÄ¿ÆÑÐÎÄÕ¡£¸ÃÑо¿ÎªÖáÍ»ÎïÖʵÄÑ¡ÔñÐÔתÔËÌṩÁËÒ»¸öеÄÊӽǣ¬¼´ÄÒÅݵļ«ÐÔתÔË¿ÉÄÜÓëÖáÍ»ÆðʼÇøÓò¸»¼¯µÄµ°°×¼¤Ã¸µ÷¿ØÏà¹Ø¡£
Ò©Ê×´æ1ÔªËÍ22²Ê½ðÕÅÑåÃñ½ÌÊÚÁªºÏ»¯¹¤Ê×´æ1ÔªËÍ22²Ê½ð³ÂöνÌÊÚ¡¢Äܶ¯Ê×´æ1ÔªËÍ22²Ê½ðÁõº£ºþ½ÌÊÚ
¹¹½¨»ùÓÚÉúÀíÏìÓ¦¼°µ÷¿ØÐÍÄÉÃ×½ð´ØµÄ¾«×¼¿ÉÊÓ¶ñÐÔÖ×ÁöÖÎÁÆ
¡¡¡¡Ê×´æ1ÔªËÍ22²Ê½ðÒ©Ê×´æ1ÔªËÍ22²Ê½ðÕÅÑåÃñ½ÌÊÚ¡¢»¯¹¤Ê×´æ1ÔªËÍ22²Ê½ð³ÂöνÌÊÚ¡¢Äܶ¯Ê×´æ1ÔªËÍ22²Ê½ðÁõº£ºþ½ÌÊÚΪÂÛÎĵÄͨѶ×÷Õߣ¬²©Ê¿ÉúÁõ·ã¡¢ÑîÌì·ãºÍ³£Ð¡ÎÀΪ¹²Í¬µÚÒ»×÷Õߣ¬ÔÚ¡¶¹ú¼Ò¿ÆѧÆÀÂÛ¡·£¨National Science Review£©·¢±íÌâΪ¡°Intelligent gold nanocluster for effective treatment of malignant tumor via tumor-specific photothermal-chemodynamic therapy with AIE guidance¡±µÄ¿ÆÑÐÂÛÎÄ¡£¸ÃÂÛÎĵõ½Á˹ú¼Ò¸ß²ã´ÎÈ˲ÅÌØÊâÖ§³Ö¼Æ»®¡¢¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð¡¢ÉÂÎ÷Ê¡×ÔÈ»¿Æѧ»ù½ð¡¢Ê×´æ1ÔªËÍ22²Ê½ð¡°ÇàÄê°Î¼âÈ˲ÅÖ§³Ö¼Æ»®¡±µÈÏîÄ¿µÄ´óÁ¦Ö§³Ö¡£
  • ½»´óÖ÷Ò³
  • ѧ²¿ÐÅÏä
  • ˼ԴBBS
  • ͼÊé¹Ý
  • ˼ԴÓʼþ
  • ÐÅÏ¢ÃÅ»§
  • ½ÌʦÖ÷Ò³

µØÖ·£ºÉÂÎ÷Ê¡Î÷°²ÊÐÑãËþÎ÷·76ºÅ£¬Óʱࣺ710061

°æȨËùÓУºÊ×´æ1ÔªËÍ22²Ê½ðÊ×´æ1ÔªËÍ22²Ê½ð

·ÃÎÊÁ¿£º

΢ÐÅƽ̨

¸ø´ó¼Ò¿ÆÆÕÒ»ÏÂÊ׳ä1ÔªÆðËͲʽð(2023ÒѸüÐÂ(V2.6.5/AI»Ø´ð)-Öйú...